1
|
Morgese MG, Colaianna M, Mhillaj E, Zotti M, Schiavone S, D'Antonio P, Harkin A, Gigliucci V, Campolongo P, Trezza V, De Stradis A, Tucci P, Cuomo V, Trabace L. Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1. Front Neurosci 2015; 9:428. [PMID: 26594145 PMCID: PMC4633524 DOI: 10.3389/fnins.2015.00428] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Accepted: 10/21/2015] [Indexed: 12/31/2022] Open
Abstract
Strong evidence showed neurotoxic properties of beta amyloid (Aβ) and its pivotal role in the Alzheimer's disease (AD) pathogenesis. Beside, experimental data suggest that Aβ may have physiological roles considering that such soluble peptide is produced and secreted during normal cellular activity. There is now suggestive evidence that neurodegenerative conditions, like AD, involve nitric oxide (NO) in their pathogenesis. Nitric oxide also possess potent neuromodulatory actions in brain regions, such as prefrontal cortex (PFC), hippocampus (HIPP), and nucleus accumbens (NAC). In the present study, we evaluated the effect of acute Aβ injection on norepinephrine (NE) content before and after pharmacological manipulations of nitrergic system in above mentioned areas. Moreover, effects of the peptide on NOS activity were evaluated. Our data showed that 2 h after i.c.v. soluble Aβ administration, NE concentrations were significantly increased in the considered areas along with increased iNOS activity. Pre-treatment with NOS inhibitors, 7-Nitroindazole (7-NI), and N6-(1-iminoethyl)-L-lysine-dihydrochloride (L-NIL), reversed Aβ-induced changes. Ultimately, pharmacological block of interleukin1 (IL-1) receptors prevented NE increase in all brain regions. Taken together our findings suggest that NO and IL-1 are critically involved in regional noradrenergic alterations induced by soluble Aβ injection.
Collapse
Affiliation(s)
- Maria G Morgese
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy
| | - Marilena Colaianna
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy ; Department of Pathology and Immunology, University of Geneva Geneva, Switzerland
| | - Emanuela Mhillaj
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy ; Department of Physiology and Pharmacology, La Sapienza, University of Rome Rome, Italy
| | - Margherita Zotti
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy
| | - Stefania Schiavone
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy
| | - Palma D'Antonio
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy
| | - Andrew Harkin
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences and Trinity College Institute of Neuroscience, Trinity College Dublin Dublin, Ireland
| | - Valentina Gigliucci
- Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences and Trinity College Institute of Neuroscience, Trinity College Dublin Dublin, Ireland
| | - Patrizia Campolongo
- Department of Physiology and Pharmacology, La Sapienza, University of Rome Rome, Italy
| | - Viviana Trezza
- Section of Biomedical Sciences and Technologies, Department of Science, University "Roma Tre," Rome, Italy
| | - Angelo De Stradis
- Department of Bio Agro-Food Sciences, The Institute of Sustainable Plant Protection, National Research Council Bari, Italy
| | - Paolo Tucci
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy
| | - Vincenzo Cuomo
- Department of Physiology and Pharmacology, La Sapienza, University of Rome Rome, Italy
| | - Luigia Trabace
- Department of Clinical and Experimental Medicine, University of Foggia Foggia, Italy
| |
Collapse
|